semaglutide chattanooga Diabetes Drug Could Help Reduce Risk for Cardiovascular Events, Study Finds SEMAGLUTIDE: "THE GAME CHANGER" Chattanooga

AMG 133 demonstrated significant dose-dependent weight loss in a phase 1 randomized, double-blind, placebo-controlled clinical trial involving participants with obesity, along with an acceptable safety and tolerability profile [124]

Hosgood et al

Wade, Prescott W

For patients with concurrent diabetes or obesity , discuss whether GLP-1 therapy is appropriate based on established indications

Clients often report fewer sick days, faster recovery, and improved resilience, making it a valuable tool for both preventative health and longevity

Common side effects These side effects are most likely to occur when starting Wegovy treatment or after your dose is increased